Role of 5-alpha Reductase in Testosterone Actions

5-α 还原酶在睾酮作用中的作用

• 批准号: 6711695
• 负责人: SHALENDER BHASIN
• 金额: $ 32.06万
• 依托单位: CHARLES R. DREW UNIVERSITY OF MED & SCI
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-04-01 至 2004-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6711695
• 关键词: adipose tissue; body composition; clinical research; dihydrotestosterone; enzyme inhibitors; estradiol; gonadotropin releasing factor; high performance liquid chromatography; hormone inhibitor; human middle age (35-64); human subject; libido; magnetic resonance imaging; male; muscle strength; outcomes research; patient oriented research; penis erection; radioimmunoassay; steroid metabolism; testosterone; testosterone 5 alpha reductase; young adult human (21-34)

DESCRIPTION (provided by applicant): Testosterone, the predominant circulating androgen in men, also serves as a prohormone that is converted in the body to two active metabolites, estradiol 17beta and 5-alpha dihydrotestosterone (DHT). Testosterone serves as the active hormone in some target tissues; however, androgen effects in other target organs require its conversion to estradiol or DHT. The role of 5-alpha reduction of testosterone in mediating its effects on the muscle and sexual function remains unclear. Therefore, the primary objective of this project is to determine whether 5-alpha reduction of testosterone to DHT is obligatory for mediating its effects on fat-free mass, muscle size, muscle strength, and leg power in men. The secondary objective is to determine whether 5-alpha reduction of testosterone is necessary for maintenance of androgen effects on sexual function (sexual desire, overall sexual activity, nocturnal penile tumescence (NPT), response to visual erotic stimulus, and penile rigidity) in men. In order to test these hypotheses about the role of 5-alpha reduction, we will compare testosterone dose response curves for each outcome measure in the absence and presence of a novel, potent 5-alpha reductase inhibitor (duasteride) that inhibits both type 1 and type 2 steroid 5-alpha -reductase isoenzymes. Healthy young men, 21-40 years of age, will be treated with a long acting GnRH agonist to suppress endogenous testosterone production, and concomitantly, randomly assigned to one of 8 groups: group 1, testosterone enanthate (TE) 50-mg weekly, plus placebo tablets daily; group 2, TE 125-mg weekly plus placebo daily; group 3, TE 300-mg weekly plus placebo daily; group 4, TE 600 mg TE weekly plus placebo; group 5, 50-mg weekly, plus duasteride 2.5-mg daily; group 6, TE 125-mg weekly, plus duasteride daily; group 7, TE 300 mg weekly, plus duasteride daily; group 8, 600-mg TE plus duasteride daily. Energy and protein intake, and exercise stimulus will be standardized. The following outcomes will be measured at baseline and after 20 weeks: body composition by DEXA scan, deuterium oxide and sodium bromide dilution; thigh muscle volume by MRI scan; muscle performance by measurements of 1-repetition maximum strength and leg power; sexual function by International Index of Erectile Function, Sexual Desire Inventory, and daily logs of sexual activity; and penile erections and rigidity during EEG-coupled, NPT recoding and in response to a visual erotic stimulus; total and free testosterone, DHT, estradiol, SHBG, and LH levels. For safety, we will follow hemoglobin/hematocrit, sleep apnea scores, AST and ALT, PSA, plasma lipids, apolipoproteins, and lipoprotein particles, and prostate examinations. A multi-disciplinary team of investigators, the use of a previously validated "Leydig Cell Clamp" model, the use of a potent inhibitor of both subtypes of 5-alpha reductase enzyme, attention to potential confounding variables such as energy intake and exercise stimulus, and power and effect size should help elucidate the role of 5-alpha reduction in mediating androgen action. This study will enhance our understanding of the biologic role of the steroid 5-alpha-reductase system, and has immediate clinical relevance in establishing whether selective androgen receptor modulators that do not undergo 5-alpha reduction would be useful as anabolic agents.

描述（由申请方提供）：替吉奥是男性中主要的循环雄激素，也是一种激素原，在体内转化为两种活性代谢物，雌二醇17 β和5-α双氢睾酮（DHT）。睾酮在某些靶组织中作为活性激素;然而，雄激素在其他靶器官中的作用需要其转化为雌二醇或DHT。睾酮的5-α减少在介导其对肌肉和性功能的影响中的作用尚不清楚。因此，本项目的主要目的是确定睾酮的5-α减少到DHT是否是强制性的，以介导其对男性无脂肪质量，肌肉大小，肌肉力量和腿部力量的影响。次要目的是确定睾酮的5-α减少是否是维持雄激素对男性性功能（性欲、总体性活动、夜间阴茎肿胀（NPT）、对视觉色情刺激的反应和阴茎僵硬）的影响所必需的。为了检验这些关于5-α减少作用的假设，我们将比较在不存在和存在抑制1型和2型类固醇5-α-还原酶同工酶的新型强效5-α还原酶抑制剂（杜洛酮）的情况下每个结果测量的睾酮剂量反应曲线。健康的年轻男性，21-40岁，将用长效GnRH激动剂治疗以抑制内源性睾酮的产生，并同时随机分配到8组之一：第1组，庚酸睾酮（TE）50-mg每周一次，每天一片安慰剂;第2组，TE 125-mg每周一次，每天一片安慰剂;第3组，TE 300-mg每周一次，每天一片安慰剂;第4组，TE 600 mg TE每周一次+安慰剂;第5组，50 mg每周一次+杜维肽2.5 mg每日一次;第6组，TE 125 mg每周一次+杜维肽每日一次;第7组，TE 300 mg每周一次+杜维肽每日一次;第8组，600 mg TE每日一次+杜维肽。能量和蛋白质的摄入，以及运动刺激将被标准化。将在基线和20周后测量以下结果：通过DEXA扫描、氧化氘和溴化钠稀释测量身体组成;通过MRI扫描测量大腿肌肉体积;通过测量1次重复最大力量和腿部力量测量肌肉性能;通过国际勃起功能指数、性欲量表和性活动每日日志测量性功能;和阴茎勃起和刚性在EEG耦合，NPT重新编码和响应视觉色情刺激;总的和游离睾酮，双氢睾酮，雌二醇，SHBG，LH水平。出于安全性考虑，我们将随访血红蛋白/红细胞压积、睡眠呼吸暂停评分、AST和ALT、PSA、血脂、载脂蛋白和脂蛋白颗粒以及前列腺检查。一个多学科的研究团队，使用先前验证的“Leydig细胞钳”模型，使用5-α还原酶两种亚型的强效抑制剂，注意潜在的混杂变量，如能量摄入和运动刺激，以及功效和效应大小，应该有助于阐明5-α减少在介导雄激素作用中的作用。这项研究将提高我们对类固醇5-α-还原酶系统的生物学作用的理解，并在确定不经历5-α还原的选择性雄激素受体调节剂是否可用作合成代谢剂方面具有直接的临床意义。